Monograph Details
|
|
Urogenital System
> Miscellaneous urogenital disorders
|
|
RENVELA |
| Manufacturer |
|
Genzyme Corporation |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Phosphate binder. |
| Generic Name |
|
Sevelamer carbonate 800mg; tabs. |
| Indications |
|
Control of serum phosphorus in patients with chronic kidney disease on dialysis. |
| Children |
|
Not recommended. |
| Adults |
|
Take with meals. Patients not taking a phosphate binder: serum phosphorus >5.5 and <7.5mg/dL: 1 tablet 3 times daily; ≥7.5mg/dL: 2 tablets 3 times daily. May switch from sevelamer HCl on a gram/gram basis. Switching from calcium acetate: sevelamer carbonate 800mg approximates calcium acetate 667mg (see literature). Titrate by 1 tablet/meal at 2-week intervals to keep serum phosphorus between 3.5–5.5mg/dL; usual max 14g/day. |
| Contraindications |
|
Hypophosphatemia. Bowel obstruction. |
| Precautions |
|
Dysphagia. Swallowing disorders. Severe GI motility disorders. Major GI tract surgery. Monitor serum bicarbonate, chloride levels. Pregnancy (Cat.C). Labor & delivery. |
| Interactions |
|
May antagonize ciprofloxacin. Separate narrow therapeutic index drugs by 1 hour before or 3 hours after sevelamer, or consider monitoring (esp. with antiarrhythmics, antiepileptics). |
| Adverse Reactions |
|
GI upset, constipation. |
| How Supplied |
|
Tabs—30, 270 |
|
|
|
|
